Thrivent Financial for Lutherans Sells 1,058,878 Shares of Progyny, Inc. (NASDAQ:PGNY)

Thrivent Financial for Lutherans decreased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 94.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 61,677 shares of the company’s stock after selling 1,058,878 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.07% of Progyny worth $1,034,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its stake in shares of Progyny by 5.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,912 shares of the company’s stock valued at $2,095,000 after buying an additional 2,947 shares in the last quarter. Comerica Bank increased its position in Progyny by 5.3% in the 1st quarter. Comerica Bank now owns 67,547 shares of the company’s stock valued at $2,577,000 after acquiring an additional 3,428 shares in the last quarter. Cetera Advisors LLC bought a new position in shares of Progyny in the first quarter worth about $321,000. SG Americas Securities LLC acquired a new position in shares of Progyny during the second quarter worth approximately $374,000. Finally, Cooper Financial Group bought a new stake in shares of Progyny during the second quarter valued at approximately $314,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on PGNY. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $17.00 price objective (down previously from $22.00) on shares of Progyny in a report on Monday. Bank of America decreased their price target on Progyny from $22.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. Leerink Partners dropped their price objective on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a report on Thursday, September 19th. Leerink Partnrs lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 7th. Finally, Canaccord Genuity Group downgraded shares of Progyny from a “buy” rating to a “hold” rating and dropped their price target for the stock from $37.00 to $24.00 in a research note on Wednesday, August 7th. Nine investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Progyny currently has an average rating of “Hold” and an average price target of $25.00.

Progyny Trading Up 0.1 %

NASDAQ:PGNY opened at $15.59 on Tuesday. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $42.08. The stock has a 50-day moving average price of $15.82 and a two-hundred day moving average price of $22.15. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 1.80 and a beta of 1.44.

Progyny (NASDAQ:PGNY) last posted its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same period in the previous year, the company posted $0.16 earnings per share. Progyny’s revenue for the quarter was up 2.0% compared to the same quarter last year. Sell-side analysts forecast that Progyny, Inc. will post 0.58 earnings per share for the current year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.